Evelo Biosciences Announces Second Quarter Financial Results

14.08.2023 - – EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early Q4 2023– Completed $25.5 Million Private Placement– Restructured and reduced secured debt with Horizon Technology Finance Corporation CAMBRIDGE, Mass., ...

Related Keywords

, Evelo Biosciences , Evelo Biosciences Inc , Horizon Technology Finance Corporation , Development Rd Expenses , Simba Gill , Chief Executive Officer , Business Highlights , Psoriasis Area , Severity Index , Private Securities Litigation Reform Act , Quarterly Report , Balance Sheets , Months Ended June ,